Flemingsberg Science leads ecosystem development with Stockholm Life Tech
Within Stockholm Life Tech, we are currently working on developing the Life Science ecosystem at Campus Flemingsberg. And the first step in this process is a review of everything from academia to innovation support.
Participating organisations in Stockholm Life Tech include Stockholm Science City Foundation, Karolinska Institutet, Flemingsberg Science, Akademiska Hus, and Karolinska Institutet Science Park. The project lead is Region Stockholm. Our objective is to make laboratories and research and innovation infrastructure available to small and medium-sized businesses in and around Stockholm’s two leading life science environments: Hagastaden and Flemingsberg. Everything we do is intended to accelerate the growth of life science companies and build the attractiveness of the Stockholm region.
Developing the ecosystem
Part of realising these goals is to develop the Life Science ecosystem. Among other things, this is about bringing together actors such as businesses, researchers, institutions, business support, politics and more, to build consensus around what is needed to further develop Life Science.
This might be about various types of support that are missing, for example advice, or the need for more collaboration, or structural barriers that need to be removed. In the project, this work has been led by KI Science Park, but from June 2022 it has been headed by Flemingsbergs Science, which means we will focus on Campus Flemingsberg.
For the remaining duration of the project, we plan to carry out an analysis of the existing ecosystem in Flemingsberg, with a focus on highlighting areas such as education, research, talent, infrastructure, business clusters, innovation support, attractiveness and expansion opportunities.
We are also planning a seminar on how the future Life Science ecosystem will look. The seminar will coincide with the official opening of A Working Lab’s co-working space at Alfred Nobels allé 10.
Now Open: Flemingsberg Science Award STARTUP 2026
Do you have a business idea that can make a difference, locally or globally? Flemingsberg Science Award STARTUP is the competition for those who want to challenge their idea, gain valuable feedback from experienced experts, and take the first step toward building something real.
Campus Flemingsberg continues to grow – more students and strong collaboration in focus
Campus Flemingsberg remains one of Sweden’s most dynamic knowledge environments. Over the past year, the number of students has increased from 24,000 to approximately 27,000. The trend is clear: the campus’s broad academic profile continues to attract a growing number of students.
Limitless Potential: Winner of the Flemingsberg Science Award 2025
Young people in disadvantaged areas often face mental health challenges and a lack of support, which can lead to isolation and destructive choices. Limitless Potential, winner of the Flemingsberg Science Award IDEA 2025, has created a safe space where creativity and social entrepreneurship come together to support youth.
Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future
In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.
En nationell resurs för morgondagens behandlingar – nu är Karolinska ATMP Centrum invigt
Med ett tydligt budskap om framtidstro och ett kraftfullt samarbete invigdes Karolinska ATMP Centrum i Flemingsberg i slutet av augusti. Centret är ett samarbete mellan Karolinska Institutet och Karolinska Universitetssjukhuset, och kommer fungera som en nationell resurs för tillverkning av avancerade terapier (ATMP), där forskning, kliniska prövningar och behandlingar smidigt samverkar för att leverera banbrytande terapier till patienter.
